


20
SITC
12

PRELIMINARY PROGRAM

SOCIETY FOR IMMUNOTHERAPY OF CANCER

October 24-28, 2012 • North Bethesda, MD

WORKSHOP • PRIMER • ANNUAL MEETING



Society for Immunotherapy of Cancer

GENERAL INFORMATION

Message from the President	2
SITC Board of Directors.....	3
SITC 2012 Organizers.....	3
General Meeting Information	4
Hotel & Travel Information	6
Support & Marketing Opportunities.....	7
SITC Trust.....	8
SITC 2012 at a Glance.....	9

ASSOCIATED PROGRAM DETAILS

Professional Development Session Information	10
Professional Development Session Schedule	11
SITC Workshop Information	12
SITC Workshop Schedule.....	13
SITC Primer Information.....	15
SITC Primer Schedule	16

SITC 27TH ANNUAL MEETING DETAILS

SITC 27 th Annual Meeting Information	17
Call for Abstracts.....	18
Young Investigator Awards.....	19
Early Career Scientists Activities	20
SITC 27 th Annual Meeting Session Descriptions.....	21
SITC 27 th Annual Meeting Schedule	22
SITC 2012 Organizers and Faculty	25
Registration Form	27

SITC INFORMATION

SITC Membership Information.....	31
SITC Membership Application.....	32
SITC Executive Staff	33



Dear Colleagues,

I would like to invite you to attend SITC 2012 in North Bethesda, MD October 24-28, 2012. As in years past, this conference will bring together leaders from around the world in the field of cancer immunology and immunotherapy for cutting edge, high-quality, scientific presentations of the latest, most relevant research and information.

At SITC, we have launched many new initiatives in the past year, including the creation of a new website, initiation of outreach and training activities, foundation of the World Immunotherapy Council for international collaborations, and an expansion of staff working hard to further our society's mission. Just as SITC continues to grow during this time of progress in the field, so too do the Annual Meeting & Associated Programs. This year, we will offer:

- Expanded activities for Early Career Scientists - our popular travel awards, breakfast roundtables, and evening network event will now be joined by the new Professional Development Session (a half day dedicated to early career scientist development);
- SITC Workshop - Focus on the Target: The Tumor Microenvironment, which will include an update on the innovative new SITC Immunoscore project;
- SITC Primer on Tumor Immunology and Cancer Immunotherapy™;
- A Hot Topic Symposium on Sunday morning;
- Keynote address by Robert Schreiber, PhD, Washington University St. Louis;
- Keynote address by *Richard V. Smalley, MD Memorial Lectureship Award* winner Theresa L. Whiteside, PhD, University of Pittsburgh Cancer Institute;
- Timely educational sessions on topics that include T Cell Modulating Strategies, Immunity of Oncolytic Viruses, Combining Immunotherapy and other Therapies, and Adoptive T Cell Transfer; and
- Stimulating social activities including a Poster Reception, Presidential Reception, and a musical performance by *The Checkpoints* (a band of SITC colleagues).

Vehicles like SITC 2012 are vital to moving our field forward, getting young scientists involved, and learning about the new fundamental discoveries that are being made as well as the new therapies that are being approved. Last year, we had a record breaking attendance of almost 800 total annual meeting attendees as well as over 200 scientific abstracts! You can help continue this trend and make this year even bigger when you review this preliminary program (and share it with colleagues) in order to plan your attendance at these excellent sessions. It is an exciting time to be a part of this field and SITC 2012 is the place to learn all about it, interact with a variety of people with interests in the field, and enjoy an atmosphere of exchange, collaboration, and innovation.

I look forward to seeing you there,



Thomas F. Gajewski, MD, PhD
SITC President



OFFICER DIRECTORS

President

Thomas F. Gajewski, MD, PhD
University of Chicago

Vice President

Francesco Marincola, MD
National Institutes of Health

Immediate Past President

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Secretary/Treasurer

Lisa H. Butterfield, PhD
University of Pittsburgh

AT LARGE DIRECTORS

Leiping Chen, MD, PhD
Yale Cancer Center

James H. Finke, PhD
Cleveland Clinic Foundation

F. Stephen Hodi, MD
Dana-Farber Cancer Institute

Pawel Kalinski, MD, PhD
University of Pittsburgh Cancer Institute

Howard Kaufman, MD
Rush University Medical Center

William J. Murphy, PhD
University of California-Davis

A. Karolina Palucka, MD, PhD
Baylor Institute for Immunology Research

Antoni Ribas, MD
UCLA Medical Center

Padmanee Sharma, MD, PhD
MD Anderson Cancer Center

SITC 2012 ORGANIZERS

Early Career Scientists Activities

- Christian Capitini, MD - *University of Wisconsin*
- William Redmond, PhD - *Earle A. Chiles Research Institute*

SITC Workshop - Focus on the Target: The Tumor Microenvironment

- Leisha A. Emens, MD, PhD - *Johns Hopkins University*
- Jerome Galon, PhD - *INSERM-Cordeliers Research Center*
- Samuel C. Silverstein, MD - *Columbia University*

SITC Primer - Primer on Tumor Immunology & Cancer Immunotherapy™

- Charles G. Drake, MD, PhD - *Johns Hopkins University*
- Mario Sznol, MD - *Yale University School of Medicine*

SITC 27th Annual Meeting

- Cornelis J.M. Melief, MD, PhD - *Leiden University Medical Center*
- Antoni Ribas, MD - *UCLA Medical Center*
- David F. Stroncek, MD - *National Institutes of Health*

SITC 2012 will take place October 24-28, 2012 at the Bethesda North Marriott Hotel and Conference Center in North Bethesda, MD. This five-day event offers the latest, most relevant research, educational sessions, and networking opportunities in a variety of formats.

SITC begins the week by hosting three associated programs. The new Professional Development Session will be on Wednesday, October 24, the two-day SITC Workshop - Focus on the Target: The Tumor Microenvironment, featuring leading experts in the field, will be held October 24-25, and the educational SITC Primer on Tumor Immunology and Cancer Immunotherapy™ will be on Thursday, October 25.

The SITC 27th Annual Meeting, which runs from Friday, October 26 to Sunday, October 28, features dynamic presentations, interactive panel discussions, and vital information on clinical trial design and regulatory issues to advance collaboration and translation of cancer immunotherapy.

The Poster Reception on Friday, October 26 and the Presidential Reception on Saturday, October 27 will serve as social and networking venues for all SITC 27th Annual Meeting attendees. Exhibits and posters will be available for viewing during these receptions.

ABSTRACT SUBMISSION

SITC invites both members and non-members to submit abstracts for review in conjunction with the SITC 27th Annual Meeting. Abstracts can be submitted online from May 7 - July 11, 2012. Abstracts submitted by the July 11 deadline will be reviewed by a committee for selection of poster and/or oral presentations. Accepted abstracts will be published in the *Journal of Immunotherapy*, an official journal of SITC. There is no fee for submitting abstracts to SITC. For more information on abstracts, please refer to page 18.

EXHIBIT BOOTHS

The SITC 27th Annual Meeting will feature exhibitors whose products and services will be on display for all meeting attendees. Pharmaceutical, biotechnology, and medical device companies; medical publishers; data management companies; and research and regulatory agencies are invited to participate in the meeting exhibition. Exhibits will be open Friday, October 26 and Saturday, October 27.

If you are interested in sponsorship and exhibit opportunities, more detailed information can be found on the "Support SITC" page of the SITC website at www.sitcancer.org/2012/annualmeeting/exhibit.

PHOTO/VIDEO POLICY

Photography and videography are prohibited in all SITC sessions, poster, and exhibit locations unless prior written approval is received from the SITC office. SITC often employs the services of a professional photographer/videographer at SITC events to capture images and audiovisual recordings for use in society archival and promotional material. Your attendance at SITC events implies your permission for images and audio/visual recordings captured during these events to be used for purposes of SITC archival and promotional materials and publications and waives your rights for compensation or ownership of these images.

RICHARD V. SMALLEY AWARD

SITC is proud to announce the recipient of the 8th Annual *Richard V. Smalley, MD Memorial Lectureship Award* as Theresa L. Whiteside, PhD, of the University of Pittsburgh Cancer Institute. This award serves to recognize sustained excellence in research in the biological therapy field. Dr. Whiteside will give the keynote address on Friday, October 26 at 8:00 am and be presented the award during the Awards Ceremony on Saturday, October 27.

YOUNG INVESTIGATOR AWARDS

SITC will offer several Young Investigator Awards recognizing excellence in oral abstract and poster presentations at the SITC 27th Annual Meeting. For more information on the Young Investigator Awards including eligibility requirements, please see page 19.

SITC "FRIEND OF THE SOCIETY" RIBBONS

SITC is committed to furthering the field of cancer immunotherapy/biologic therapy through the establishment of a trust to support research, training, and education. SITC members can show their support for this Trust and their commitment to their field by purchasing a "Friend of the Society" ribbon. "Friend of the Society" ribbons are designed to be worn on the name badges of delegates attending SITC 2012. Ribbons may be acquired for a minimum donation of \$50 and can be purchased personally or for distribution to other recipients. In addition to wearing ribbons, all donors will be recognized on signs at SITC 2012 and on the Society's website.

EARLY CAREER SCIENTISTS ACTIVITIES

The Early Career Scientists (ECS) Committee was established to partner with SITC leadership to address the needs of early career scientists in the fields of immunology and biological therapy.

Members of the Committee include students, postdoctoral fellows, and early career professionals in academia, industry, and regulatory agencies. ECS Committee members participate in many activities and continually seek opportunities for early career scientists to advance SITC's mission and programming. The main goal of the committee is to leverage society relationships and resources to enhance the career development of outstanding young investigators in the field.

For SITC's 27th Annual Meeting, the ECS Committee has organized several events to connect early career scientists with leaders in the field of cancer immunotherapy on a variety of career development topics. Space for these events is limited and priority will be given to early career scientists. Please register in advance.

REGISTRATION

Registration for SITC 2012 begins May 7, 2012 and can be done online at www.sitcancer.org or by completing the registration form. SITC members receive reduced registration fees for all educational programs. All non-members have the opportunity to submit applications for membership and receive reduced registration fees. Early registration discounts will also be offered to those registering by September 9, 2012. Pre-registered attendees will have their meeting materials for SITC 2012 available for pick up at the SITC registration desk at the Bethesda North Marriott Hotel & Conference Center. On-site registration will be available October 23-28, however, fees will increase.

Registration Desk Hours

Tuesday, October 23	5:00 pm - 8:00 pm
Wednesday, October 24	7:00 am - 5:00 pm
Thursday, October 25	7:00 am - 6:00 pm
Friday, October 26	7:00 am - 6:00 pm
Saturday, October 27	7:00 am - 5:00 pm
Sunday, October 28	7:30 am - 12:00 pm

GUEST REGISTRATION

Guests accompanying registered SITC 27th Annual Meeting attendees may be registered at the guest rate of \$125. Guest registration grants admittance to the SITC 27th Annual Meeting evening social functions and cannot be used for admittance to educational sessions or other activities. Society members or authors/co-authors of abstracts may not use the guest registration category. Please see the registration form on page 27 to register a guest.

PRESS REGISTRATION

Members of the press may register without charge for SITC 2012 with proof of credentials. For more information, please visit the SITC website at www.sitcancer.org or contact Jennifer Warren, Assistant Director of Communications, at 414-271-2456.

REFUND POLICY

Refund requests must be submitted in writing to the SITC office by September 24, 2012. A \$50 processing fee will be charged for all cancellations. Refunds will be processed after the meeting and no refunds will be granted if the cancellation is received after September 24, 2012.

PURCHASE YOUR "FRIEND OF THE SOCIETY" RIBBON

Show your support for the field!
Purchase your "Friend of the Society" Ribbon at the SITC Registration Desk for a minimum donation of \$50. All proceeds go to the SITC Trust to support research, training, and education.

FRIEND OF THE SOCIETY

HOTEL INFORMATION

Reservation Deadline: September 24, 2012

SITC has reserved a block of rooms at the Bethesda North Marriott Hotel & Conference Center, the venue of SITC 2012, to accommodate meeting participants, supporters and exhibitors. To make a reservation, please follow the instructions below or visit www.sitcancer.org/2012/hotel.

SITC 2012 attendees will receive the discounted conference room rate of \$199 per night for a single or a double room when mentioning SITC as well as free internet access in your guest room. This price does not include tax. Reservations must be made by September 24, 2012 to receive the discounted SITC 2012 room rate. SITC cannot guarantee this rate for reservations made beyond this date or once the room block reaches capacity.

Bethesda North Marriott Hotel & Conference Center

5701 Marinelli Road
Bethesda, MD 20852
Phone: 301-822-9200

Reservation Phone Number: 1-506-474-2009 or

Toll Free 1-800-266-9432 (mention SITC to get the discounted rate)

Reservation Web Site: www.sitcancer.org/2012/Hotel

Room Rate: \$199/night (single or double) does not include tax

SITC has a limited number of discounted rooms available for students/postdoctoral fellows on a first-come first-served basis. In order to obtain this rate (\$179/night, does not include tax), you must be registered as a student for the meeting and contact the SITC office at 414-271-2456.

BETHESDA, MD - CITY INFORMATION

The average temperature in Bethesda, MD in November ranges between 36-55 degrees Fahrenheit. Bethesda, MD averages approximately 3.44 inches of precipitation in November.

Montgomery County Maryland**Convention & Visitors Bureau**

111 Rockville Pike, Suite 800
Rockville, MD 20850
Phone: 240-777-2060 or toll free at 877-789-6904
Website: www.visitmontgomery.com

For more information on things to do within Washington, DC, contact the Washington DC Convention & Visitors Bureau at phone 202-789-7000 or www.washington.org.

TRAVEL / TRANSPORTATION

Bethesda North Marriott Hotel is located within 20 miles of Washington, DC and access to the city is easy with taxis or the Metro.

Major Airports

Three airports serve the Washington, DC area: Ronald Reagan Washington National Airport (DCA), Washington Dulles International Airport (IAD) and Baltimore Washington International Airport (BWI). For more information, visit their websites:

- Ronald Reagan Washington National Airport:
www.mwaa.com/national
- Washington Dulles International Airport:
www.metwashairports.com/Dulles/index.html
- Baltimore Washington International Airport:
www.bwiairport.com

For travel tips and security updates, please visit www.tsa.gov.

Taxis

Taxi stands are located at all the major airports as well as most hotels, attractions and shopping centers. From the Ronald Reagan National Airport to the Bethesda North Marriott Hotel, fares are approximately \$55-60*. From the Washington Dulles International Airport, the fare is \$60-65* to the hotel. From the Baltimore Washington International Airport, expect to pay \$85*.

Metro

The Metro train operates Monday through Sunday at varying hours. Base fares start at \$1.65* per trip (including trips between all downtown points). One-day tickets can be purchased for \$7.80*, which allows unlimited travel after 9:30 am on weekdays and all day on weekends. To calculate the distance and fares between two stops, visit www.metroopensdoors.com.

The Bethesda North Marriott Hotel is located across the street from the White Flint Metro Station (Red Line). Individuals flying into Ronald Reagan National Airport can take the Metro to the hotel for approximately \$5 (one-way).

Shuttle

The hotel does not provide shuttle service from any of the airports to the hotel.

**Fares are approximate and subject to change.*

www.sitcancer.org/support

Having a presence at SITC 2012 is a great way to gain publicity for your institution, capture potential customers, and align your company with the biggest dedicated cancer immunotherapy meeting and best science in the field. SITC has branding opportunities and marketing solutions available no matter what your goal. Overviews of the available opportunities are outlined below. For more details, please visit the “Support SITC” section of the SITC website at www.sitcancer.org/support or contact Margaret Lecey, Membership and Development Manager, at 414-271-2456 or mlecey@sitcancer.org.

MARKETING & PROMOTIONAL OPPORTUNITIES

Item Support

SITC offers organizations interested in reaching important stakeholders at SITC 2012 opportunities to have your logo seen by attendees in prominent locations. All item support requests will be considered. For a listing of the available items for support, please download the support application at www.sitcancer.org/support.

Exhibit Booths

The SITC exhibit area is strategically located to maximize your face-to-face interaction with delegates as they enjoy meals or beverage breaks and walk among the posters located directly adjacent to the session rooms. Three different booth and pricing options are available to meet your needs. For more information, visit www.sitcancer.org/2012/annualmeeting/exhibit.

Product Theaters

This industry-driven forum is an educational opportunity to inform meeting attendees about your service and/or technology. The Product Theaters will occur in a large amphitheater, allowing for maximum attendance at your presentation. The prominent Friday and Saturday lunch hours as well as the Sunday breakfast times are reserved for these presentations and are unopposed by any other SITC educational programming.

Technology

This industry-driven technical workshop is designed to provide hands-on training and demonstrations of your technology. The space is more intimate than the Product Theaters to give more of a personal interaction during this workshop time. The prominent Friday and Saturday lunch hours, as well as the Sunday breakfast times, are reserved for these demonstrations to maximize your attendance.

Advertisements

Get your logo and key messaging to program attendees, website viewers, and SITC members via the advertising outlets available for SITC 2012 including program books, e-newsletters, web banner ads, and registration bag inserts.

EDUCATIONAL SUPPORT

General Program Support

Get acknowledgement while supporting the educational mission and goals of the program through an unrestricted educational grant. Benefits of support are numerous including prominent logo placement at the meeting and online, in addition to other acknowledgements of support throughout the year via electronic communications and in-person presentations. View the support levels and benefits of each on the “Support SITC” page of the SITC website at www.sitcancer.org/support.

Program Books

Have your logo and full-page acknowledgement included in the most referenced publications onsite containing schedules, abstracts, and faculty listings.

Online Program Proceedings

Connect with delegates through display of your name and logo on highly-accessed web pages that provide program summaries, speaker slides, and schedules.

Young Investigator Travel Awards

Show your support of the early career scientists by funding one or all of the awardees' attendance at the SITC 27th Annual Meeting. Travel awards are granted to young investigators that show excellence and outstanding scientific merit in their submitted abstract for the meeting.

In 2009, the SITC Board of Directors established the SITC Trust as a mechanism to support education and research in cancer immunotherapy to help find treatments and cures for the millions of people suffering from cancer. As part of the Society's 2012-2015 Strategic Plan, a committee chaired by Drs. Michael Atkins and Ronald Herberman was established and charged with overseeing the growth and development of the SITC Trust in order to lay the groundwork necessary to successfully achieve the mission and goals of the Trust.

The Trust receives unrestricted gifts and contributions for investments to increase research and educational opportunities for members, healthcare professionals, and the public in the field of biological therapy/immunotherapy of cancer and support opportunities for collaboration in alignment with the Society's mission, core values, and goals outlined in its Strategic Plan.

Gifts to the SITC Trust can be made through a general charitable contribution or through the purchase of "Friend of the Society" ribbons. More information on the SITC Trust, as well as a contribution form can be found on the Society's website at www.sitcancer.org/support.

General Charitable Gifts*

Contributions in any amount are welcomed to support the mission and efforts of the Trust. Donations can be made on the meeting registration forms or by contacting the SITC office at 414-271-2456 or info@sitcancer.org for a donation form. All SITC Trust donors will be recognized on meeting signage as well as on the Society's website for the year following the donation.

SITC "Friend of the Society" Ribbons*

All gifts designated for the SITC "Friend of the Society" fund, received prior to SITC 2012, will receive ribbons that can be worn on delegate name badges to note your special commitment to the field as well as be recognized on SITC 2012 signs. Ribbons may be acquired for a minimum donation of \$50 and can be purchased personally or for distribution to others.

SITC "Friend of the Society" ribbons can be purchased through the following methods:

- Online meeting registration form (www.sitcancer.org/2012/registration)
- Printed meeting registration form (found on page 27)
- SITC Trust donation form (found online)

**As a 501(c)(3) organization, donations made to SITC are tax deductible as charitable contributions to the extent allowed by law. For more information on these and other opportunities with SITC, visit www.sitcancer.org/support or contact the SITC office at 414-271-2456 or info@sitcancer.org.*

ATTENTION

Early Career Scientists, Young Investigators, and Students!



Join the Early Career Scientists (ECS) Committee for the following educational and networking opportunities taking place during SITC 2012.

- ECS Professional Development Session - Wednesday, October 24 from 1:30 pm - 5:30 pm
- ECS Networking Event - Friday, October 26 from 8:00 pm - 10:00 pm
- ECS "Meet-the-Expert" Breakfast on Saturday, October 27 from 7:00 am - 7:45 am

For more information on these events and the Early Career Scientist Committee, please see pages 10 and 20. To find out how you can become a member of this dynamic committee, contact Margaret Lecey, Membership and Development Manager, at 414-271-2456 or mlecey@sitcancer.org.

WEDNESDAY, OCTOBER 24

7:00 am - 8:00 am	Continental Breakfast
8:00 am - 5:00 pm	SITC Workshop - Focus on the Target: The Tumor Microenvironment
1:30 pm - 5:30 pm	Early Career Scientists Professional Development Session

THURSDAY, OCTOBER 25

7:00 am - 8:00 am	Continental Breakfast
8:00 am - 5:00 pm	SITC Workshop - Focus on the Target: The Tumor Microenvironment
8:00 am - 5:00 pm	SITC Primer on Tumor Immunology and Cancer Immunotherapy™

FRIDAY, OCTOBER 26

7:00 am - 7:45 am	New Member Breakfast Gathering
7:00 am - 7:45 am	Continental Breakfast
7:50 am - 8:00 am	SITC 27 th Annual Meeting Begins/President's Welcome
8:00 am - 8:45 am	Richard V. Smalley, MD Memorial Lectureship: Theresa L. Whiteside, PhD - <i>University of Pittsburgh Cancer Institute</i>
8:45 am - 11:30 am	Plenary Session 301: T Cell Modulating Strategies
11:30 am - 1:30 pm	Lunch with Exhibits, Poster Viewing, and Presentations
1:30 pm - 3:00 pm	Concurrent Session 304: DC Subsets/Cancer Vaccines
1:30 pm - 3:00 pm	Concurrent Session 305: Targeting Immune Suppression
3:15 pm - 5:15 pm	Plenary Session 306: Immunity of Oncolytic Viruses
5:15 pm - 5:30 pm	Plenary Session 307: World Immunotherapy Council (WIC) Update
5:30 pm - 5:45 pm	Plenary Session 308: US Food and Drug Administration (FDA) Update
5:45 pm - 6:15 pm	SITC Membership Business Meeting
Immediately following the Business Meeting - 8:00 pm	Poster and Networking Reception
8:00 pm - 10:00 pm	Early Career Scientists Networking Event

SATURDAY, OCTOBER 27

7:00 am - 7:45 am	Early Career Scientists "Meet the Expert" Breakfast (ticket required)
8:00 am - 8:45 am	Keynote Address: Robert D. Shreiber, PhD - <i>Washington University St. Louis</i>
8:45 am - 11:30 am	Plenary Session 401: Combining Immunotherapy and Other Therapies
11:30 am - 1:30 pm	Lunch with Exhibits, Poster Viewing and Presentations
1:30 pm - 3:00 pm	Concurrent Session 404: T Cell Manufacture and Potency Testing
1:30 pm - 3:00 pm	Concurrent Session 405: Single Cell High Throughput Technologies Immune Monitoring
3:15 pm - 4:50 pm	Plenary Session 406: Presidential Abstract Session
4:50 pm - 5:20 pm	Plenary Session 407: National Cancer Institute (NCI) Update
5:20 pm - 5:50 pm	Plenary Session 408: Cancer Immunotherapy Trials Network (CITN) Update
5:50 pm - 6:15 pm	Awards Ceremony
Immediately following the Awards Ceremony - 8:00 pm	Presidential Reception with Poster Viewing
8:00 pm	<i>The Checkpoints</i> Performance

SUNDAY, OCTOBER 28

8:00 am - 10:15 am	Plenary Session 500: Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
10:15 am	Annual Meeting Adjourns
10:30 am - 12:00 pm	Hot Topic Symposium

EARLY CAREER SCIENTISTS PROFESSIONAL DEVELOPMENT SESSION

Wednesday, October 24, 2012

(Separate registration fee required)

Program Purpose

This half day event is intended to educate early career attendees in a large group didactic setting about relevant career development topics that lead to successful scientific careers in cancer immunotherapy and provide an opportunity to network with leaders in the field.

Organizers

Christian Capitini, MD – *University of Wisconsin*

William Redmond, PhD – *Earle A. Chiles Research Institute*

Intended Audience

The audience for this educational program includes graduate, medical, and post baccalaureate students; clinical fellows; post-doctoral fellows; assistant professors; and other early career professionals.

Topics

- Getting a Grant: Career Development Awards
- Managing The Lab/Preparing For Tenure
- Career Panel: Academia, Industry, Government

Program Goals

- Enhance approaches to obtaining external funding including grant types, grant writing and preparation, with a focus on preparing National Institutes of Health K series of grants.
- Understand how to develop and manage a productive laboratory, including recruiting strong graduate students and post-doctoral fellows, and preparing for the tenure review process.
- Explore career options in academia, industry, and government available to scientists interested in cancer immunotherapy.

Expected Learner Outcomes

Upon completion of this program, early career scientists will be able to:

- Discuss approaches to prepare for their first K awards.
- List strategies to find strong graduate students and postdoctoral fellows.
- Define how to organize a research portfolio to prepare for the tenure process.
- Describe career opportunities available specifically in cancer immunotherapy in academia, industry, and government.

(Schedule subject to change)

WEDNESDAY, OCTOBER 24

1:30 pm – 1:35 pm	Welcome and Introductions
	Organizers: Christian Capitini, MD - <i>University of Wisconsin</i>
	William Redmond, PhD - <i>Earle A. Chiles Research Institute</i>
Session 150: Getting a Grant	
1:35 pm – 1:55 pm	Getting a K99/Roo Award from the National Institutes of Health
	Shari Pilon-Thomas, PhD - <i>H. Lee Moffitt Cancer Center and Research Institute</i>
1:55 pm – 2:00 pm	Questions and Answers
2:00 pm – 2:20 pm	Getting a K Award from the National Institutes of Health
	To Be Announced
2:20 pm – 2:25 pm	Questions and Answers
2:25 pm – 2:40 pm	<i>Refreshments and Networking</i>
Session 151: Managing The Lab/Preparing For Tenure	
2:40 pm – 3:00 pm	New Primary Investigators: Attracting Students And Post-Docs, Preparing For Tenure
	To Be Announced
3:00 pm – 3:05 pm	Questions and Answers
3:05 pm – 3:25 pm	The Business Of Research
	Lisa H. Butterfield, PhD - <i>University of Pittsburgh</i>
3:25 pm – 3:30 pm	Questions and Answers
3:30 pm – 3:45 pm	<i>Refreshments and Networking</i>
Session 152: Career Panel	
3:45 pm – 4:05 pm	Academia
	Ana Anderson, PhD - <i>Harvard Medical School</i>
4:05 pm – 4:25 pm	Industry
	Amy Wesa, PhD - <i>CelSense, Inc.</i>
4:25 pm – 4:45 pm	Government
	Raj K. Puri, MD, PhD - <i>US Food and Drug Administration, CBER</i>
4:45 pm – 5:00 pm	Questions and Answers
5:00 pm – 5:30 pm	Networking Event

SITC WORKSHOP - FOCUS ON THE TARGET: THE TUMOR MICROENVIRONMENT

Wednesday - Thursday, October 24-25, 2012

(Separate registration fee required)

Program Purpose

The development of cancer has historically been attributed to genomic alterations of normal host cells, with cancer treatments historically targeting the malignant cell itself. It is now clear that tumor growth and development is a complex process that involves both malignant transformation and the influence of normal host cells, including fibroblasts, endothelial cells, lymphocytes, monocytes, and macrophages. The tumor microenvironment has emerged as a critical target for cancer diagnosis, prognosis, and therapy.

This two-day workshop on the tumor microenvironment will include presentations from thought leaders in the field and cover topics from basic tumor immunobiology to clinical immunotherapy trials that incorporate agents that modulate the tumor microenvironment. It will end with a presentation of progress on the development of the immunoscore - an ongoing initiative to promote the incorporation of an analysis of immune infiltrates within primary tumors as part of their standard pathologic evaluation for cancer diagnosis, prognosis, and therapy.

Organizers

- Leisha Emens, MD, PhD - *Johns Hopkins University*
- Jerome Galon, PhD - *INSERM-Cordeliers Research Center*
- Samuel Silverstein, MD - *Columbia University*

Intended Audience

The audience for this program is basic scientists and clinical investigators from academic institutions, industry, and regulatory agencies. The audience includes clinicians, translational and basic researchers, graduate students, and postdoctoral fellows involved in cancer research.

Topics

- Cells of the Immune System in the Tumor Microenvironment
- Stromal Elements of the Tumor Microenvironment
- Inflammation and Immune Trafficking
- Remodeling the Tumor Microenvironment to Promote Tumor Regression
- Monitoring Immune Responses with the Tumor Microenvironment
- Clinical Trials: Provoking Immunity in the Tumor Microenvironment
- Immunoscore

Program Goals

- Critically review the role of the immune system in cancer growth and progression and in cancer control and therapy.
- Identify the distinct cellular and molecular components of the tumor microenvironment and how they interact in positive and negative ways with the host immune system.
- Explore current data on the intersection of inflammation and immune infiltrates within the tumor site, defining mechanisms of immune cell trafficking, and identifying opportunities for therapeutic manipulation to improve immune-based therapies.
- Discuss strategies for manipulating cells within the tumor microenvironment, including T cells, myeloid-derived suppressor cells, and other inflammatory cells, to promote tumor regression.
- Review approaches for characterizing and monitoring immune responses within the tumor microenvironment, including novel imaging techniques, and innovative epigenetic and genomic technologies for profiling therapeutic responses.
- Present what has been learned from successful clinical interventions that target the tumor microenvironment to enhance tumor immunity and highlight how to build on these observations to further improve cancer outcomes.
- Discuss the progress, opportunities, and challenges involved in developing the immune score as one standard component of the pathologic evaluation of newly diagnosed cancers.

Expected Learner Outcomes

Upon completion of this program, the participants will be able to:

- Summarize how the immune system can promote evolving malignancies and, conversely, how it can control cancers and be harnessed for therapeutic benefit.
- Explain the details of how a variety of cellular constituents and signaling pathways within the tumor microenvironment collaborate to promote tumor growth or regression.
- Describe how immune cells gain access to tumors and how they can be characterized with new imaging techniques and measured with new technologies for both predicting and profiling responses.
- Interpret the current rationale and clinical strategies for both profiling and therapeutically targeting the tumor microenvironment within cancer patients.
- Describe the features and clinical relevance of the immune score and the challenges involved in harmonizing the methods and evaluation of immune infiltrates to facilitate the incorporation of the immune score into the standard pathologic evaluation of newly diagnosed tumors.

(Schedule subject to change)

WEDNESDAY, OCTOBER 24

Day 1: An Integrative View of the Tumor Microenvironment	
7:00 am - 8:00 am	Registration
7:00 am - 8:00 am	Continental Breakfast
Session 100: Keynote Address	
8:00 am - 9:00 am	Immunity in Cancer Growth and Progression
	Nicholas P. Restifo, MD - <i>National Cancer Institute</i>
Session 101: Cells of the Immune System in the Tumor Microenvironment	
9:00 am - 9:30 am	Integrative Cancer Immunology: Importance of T Cells
	Jerome Galon, PhD - <i>INSERM-Cordeliers Research Center</i>
9:30 am - 10:00 am	T Cells and Antigens
	Pierre G. Coulie, MD, PhD - <i>De Duve Institute and University of Louvain</i>
10:00 am - 10:30 am	<i>Refreshments and Networking</i>
Session 102: Stromal Elements of the Tumor Microenvironment	
10:30 am - 11:00 am	Lymphoid/Vascular Elements
	George Coukos, MD, PhD - <i>University of Pennsylvania Medical Center</i>
11:00 am - 11:30 am	Immune Suppression by Stromal Cells
	David H. Munn, MD - <i>Georgia Health Sciences University</i>
11:30 am - 12:00 pm	Direct/Indirect Antigen Presentation/Cell Interactions
	Hans Schreiber, MD, PhD - <i>University of Chicago</i>
12:00 pm - 1:30 pm	<i>Lunch Break and Networking</i>
Session 103: Inflammation and Immune Trafficking	
1:30 pm - 2:00 pm	Cytokines/Chemokines/Inflammatory Signatures
	Thomas F. Gajewski, MD, PhD - <i>University of Chicago</i>
2:00 pm - 2:30 pm	Chemokines and MDSC
	Vincenzo Bronte, MD - <i>University of Verona</i>
2:30 pm - 3:00 pm	A Critical Concentration of Cytolytically Active Tumor Antigen-specific CD8+T-cells Is Required to Eradicate Cognate Antigen-expressing Murine Melanoma
	Samuel C. Silverstein, MD - <i>Columbia University</i>
3:00 pm - 3:30 pm	Manipulating MDSC to Promote Regression
	Dmitry I. Gabrilovich, MD, PhD - <i>H. Lee Moffitt Cancer Center and Research Institute</i>
Session 104: Keynote Address	
3:30 pm - 4:30 pm	Improving Cancer Immunotherapies: Future Directions
	Glenn Dranoff, MD - <i>Dana-Farber Cancer Institute</i>

(Schedule subject to change)

THURSDAY, OCTOBER 25

Day 2: Manipulating the Tumor Microenvironment for Therapeutic Benefit	
7:00 am - 8:00 am	Continental Breakfast
Session 200: Remodeling the Tumor Microenvironment to Promote Tumor Regression	
8:00 am - 8:30 am	Oncogene Inactivation and CD4+ T Cells
	Dean W. Flesher, MD, PhD - <i>Stanford University School of Medicine</i>
8:30 am - 9:00 am	Immune Checkpoint Modulation and the Tumor Microenvironment
	Drew Pardoll, MD, PhD - <i>Johns Hopkins University School of Medicine</i>
9:00 am - 9:30 am	Cytokines/Chemokines
	Weiping Zou, MD, PhD - <i>University of Michigan</i>
9:30 am - 10:00 am	Manipulating T Cells to Promote Regression
	Laurence Cooper, MD, PhD - <i>MD Anderson Cancer Center</i>
10:00 am - 10:30 am	<i>Refreshments and Networking</i>
Session 201: Monitoring Immune Responses with the Tumor Microenvironment	
10:30 am - 11:00 am	Deep Imaging/Cell Interactions
	Nicholas Gascoigne, PhD - <i>The Scripps Research Institute</i>
11:00 am - 11:30 am	Intravital Imaging of NK/T Cell Dynamics During Tumor Regression
	Philippe Bousso - <i>INSERM U668</i>
11:30 am - 12:00 pm	Epigenetics and Immune Monitoring
	Ulrich Hoffmueller, PhD - <i>Epiontis GmbH</i>
12:00 pm - 12:30 pm	Immune Response Signatures and Patient Survival
	Mary L. Disis, MD - <i>University of Washington</i>
12:30 pm - 2:00 pm	<i>Lunch Break and Networking</i>
Session 202: Clinical Trials: Provoking Immunity in the Tumor Microenvironment	
2:00 pm - 2:30 pm	sp MABs (HER2/VEGFR2) and Vaccine
	Leisha A. Emens, MD, PhD - <i>Johns Hopkins University</i>
2:30 pm - 2:50 pm	Cialis/Revlimid and Immunity
	Ivan Borrello, MD - <i>Johns Hopkins University School of Medicine</i>
2:50 pm - 3:10 pm	TLR and DC Vaccine
	Antoni Ribas, MD - <i>UCLA Medical Center</i>
3:10 pm - 3:30 pm	Sunitinib and Immunity
	Brian I. Rini, MD - <i>Cleveland Clinic Taussig Cancer Center</i>
Session 203: Immunoscore	
3:30 pm - 3:50 pm	The Immunoscore: A Proposal for a New Classification of Cancer in the Era of Immunotherapies
	Jerome Galon, PhD - <i>INSERM-Cordeliers Research Center</i>
3:50 pm - 4:10 pm	The Impact of Immune Cell Infiltration on Patient Prognosis
	Alessandro Lugli, MD - <i>Institut of Pathology University of Bern</i>
4:10 pm - 4:30 pm	A Strategic View of the Immunoscore
	Bernard A. Fox, PhD - <i>Earle A. Chiles Research Institute</i>
4:30 pm - 4:50 pm	Immune System and Cancer: Importance of the Immunoscore
	Francesco Marincola, MD - <i>National Institutes of Health</i>
4:50 pm - 5:00 pm	Closing Comments

SITC PRIMER ON TUMOR IMMUNOLOGY AND CANCER IMMUNOTHERAPY™

Thursday, October 25, 2012

(Separate registration fee required)

Program Purpose

Understanding of tumor immunobiology has increased dramatically in recent years, leading to the successful development of new immune-based treatment options to improve cancer outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Prominent investigators will summarize central themes and recent research in tumor immunology and cancer immunotherapy including innate immunity, dendritic cells, T cell differentiation, antibody therapy, and the tumor microenvironment as well as recent advances in the clinical application of cancer vaccines, coinhibition and costimulation of immune cells for immunotherapy, adoptive immunotherapy, and immune monitoring in clinical trials of cancer immunotherapies. These topics will be addressed in a series of lectures by thought leaders in the field and through interactive question and answer discussions.

Organizers

- Charles Drake, MD, PhD - *Johns Hopkins University*
- Mario Sznol, MD - *Yale University School of Medicine*

Intended Audience

The audience for this annual, one-day educational program includes students, postdoctoral fellows, and technicians from academia and industry as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy.

Topics

- Innate Immunity
- Dendritic Cells
- T Cell Differentiation: From Naïve to Effector Cells
- T Cell Intracellular Signaling
- Immunobiology of the Tumor Microenvironment
- Tumor Antigen, Tumor Immunogenicity and Immunization
- Coinhibition and Costimulation in Cancer Immunotherapy
- Adoptive Immunotherapy
- Immunology of Antibodies as Therapy

Program Goals

- Interpret a framework of basic immunology to facilitate understanding of more sophisticated principles of tumor immunology and immunotherapy.
- Provide a common terminology and knowledge base for participants from many different areas.
- Review the biology of innate immunity, dendritic cells, T cell differentiation and intracellular signaling, and the tumor microenvironment as related to recent advances in cancer immunotherapies.
- Summarize the principles of and recent advances in the application of tumor antigens for immunization, coinhibition and costimulation of immune cells, adoptive immunotherapy, and immune monitoring in clinical trials of cancer immunotherapies.
- Provide the opportunity for dialogue and professional interactions that promote collaboration and scientific exchange.

Expected Learner Outcomes

Upon completion of this program, the participants will be able to:

- Understand the key principles of tumor immunology and immunotherapy.
- Describe the role of innate immunity, T cell differentiation and signaling, and the tumor microenvironment in cancer immunotherapies.
- Discuss recent research and clinical applications of tumor immunization, immune coinhibition and costimulation, adoptive immunotherapy, and biomarkers.
- Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer.

(Schedule subject to change)

THURSDAY, OCTOBER 25

7:00 am - 8:00 am	Registration
7:00 am - 8:00 am	Continental Breakfast
8:00 am - 8:05 am	Welcome and Introductions
	Organizers: Charles G. Drake, MD, PhD - <i>Johns Hopkins University</i>
	Mario Sznol, MD - <i>Yale University School of Medicine</i>
8:05 am - 8:45 am	Session 250: Innate Immunity
	Willem W. Overwijk, PhD - <i>MD Anderson Cancer Center</i>
8:45 am - 8:55 am	Audience Response/Questions and Answers
8:55 am - 9:35 am	Session 251: Dendritic Cells
	Madhav Dhodapkar, MD - <i>Yale University</i>
9:35 am - 9:45 am	Audience Response/Questions and Answers
9:45 am - 10:00 am	<i>Refreshments and Networking</i>
10:00 am - 10:40 am	Session 252: Immunology of Antibodies as Therapy
	Louis M. Weiner, MD - <i>Georgetown University Medical Center</i>
10:40 am - 10:50 am	Audience Response/Questions and Answers
10:50 am - 11:30 am	Session 253: T Cell Differentiation: From Naïve to Effector Cells
	Susan Kaech, PhD - <i>Yale University</i>
11:30 am - 11:40 am	Audience Response/Questions and Answers
11:40 am - 12:20 pm	Session 254: Immunobiology of the Tumor Microenvironment
	Thomas F. Gajewski, MD, PhD - <i>University of Chicago</i>
12:20 pm - 12:30 pm	Audience Response/Questions and Answers
12:30 pm - 1:25 pm	<i>Lunch Break and Networking</i>
1:25 pm - 2:05 pm	Session 255: T Cell Intracellular Signaling
	Jonathan Powell, MD - <i>Johns Hopkins Hospital</i>
2:05 pm - 2:15 pm	Audience Response/Questions and Answers
2:15 pm - 2:55 pm	Session 256: Tumor Antigen, Tumor Immunogenicity and Immunization
	Pedro J. Romero, MD - <i>University of Lausanne</i>
2:55 pm - 3:05 pm	Audience Response/Questions and Answers
3:05 pm - 3:20 pm	<i>Refreshments and Networking</i>
3:20 pm - 4:00 pm	Session 257: Coinhibition and Costimulation in Cancer Immunotherapy
	Charles G. Drake, MD, PhD - <i>Johns Hopkins University</i>
4:00 pm - 4:10 pm	Audience Response/Questions and Answers
4:10 pm - 4:50 pm	Session 258: Adoptive Immunotherapy
	Cassian Yee, MD - <i>Fred Hutchinson Cancer Research Center</i>
4:50 pm - 5:00 pm	Audience Response/Questions and Answers

October 26-28, 2012

(Separate registration fee required)

Purpose

The SITC 27th Annual Meeting provides a multidisciplinary educational environment composed of cutting-edge research, informative oral presentations, poster presentations, and valuable networking opportunities unique to SITC. For more information about abstract submission and awards, see pages 18 - 19 or visit www.sitcancer.org.

Organizers

- Cornelis J.M. Melief, MD, PhD - *Leiden University Medical Center*
- Antoni Ribas, MD - *UCLA Medical Center*
- David F. Stroncek, MD - *National Institutes of Health*

Intended Audience

The audience for the SITC 27th Annual Meeting is basic and clinical investigators from academic institutions, industry, and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.

Topics

The SITC 27th Annual Meeting consists of lectures, oral abstracts, and poster presentations, which will address the latest developments in the following areas:

- Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
- Combining Immunotherapy and Other Therapies
- DC Subsets/Cancer Vaccines
- Immunity of Oncolytic Viruses
- Immunotherapy Combinations *
- Innate Immunity in Cancer *
- Single Cell High Throughput Technologies Immune Monitoring
- T Cell Manufacture and Potency Testing
- T Cell Modulating Strategies
- Targeted Therapies and Anti-Tumor Immunity *
- Targeting Immune Suppression
- Therapeutic Monoclonal Antibodies in Cancer *
- Tumor Microenvironment *
- Tumor Vasculature, Chemokines and Lymphocyte Trafficking to the Tumor *

* Denotes poster only category.

SPECIAL UPDATE SESSIONS

The SITC 27th Annual Meeting offers a unique forum for special updates, major national and international initiatives, and important society projects including:

- National Cancer Institute (NCI) Update
- US Food and Drug Administration (FDA) Update
- Cancer Immunotherapy Trials Network (CITN) Update
- World Immunotherapy Council (WIC) Update

Program Goals

- Exchange information on the most recent advances in tumor immunology and cancer immunotherapy.
- Convey recent advances in biology and immunotherapy as they relate to specific cancers and various immunotherapy modalities, cell subsets, animal models, and aspects of negative regulation in the tumor microenvironment.
- Identify promising research opportunities, new techniques, and clinical applications incorporating these advances.
- Establish dialogue between academia, industry, and government on these advances.

Expected Learner Outcomes

Upon completion of this program, the participants will be able to:

- Summarize the most recent advances in tumor immunology and cancer immunotherapy.
- Integrate recent advances in cancer immunology and immunotherapy into basic, clinical, and translational research.
- Incorporate new research and techniques into clinical applications for cancer immunotherapy.
- Establish and solidify collaborations among the various members of academia, industry, government, and clinical practices to promote clinical evaluation of these advances in more efficient trials.

The SITC 27th Annual Meeting is a non-accredited continuing education event. No credits are offered for physician participation in this educational program.



Party with The Checkpoints!

**Saturday, October 27, 2012
8:00 pm**

**Grand Ballroom E, Bethesda North
Marriott Hotel & Conference Center**

SITC invites members and non-members to submit abstracts for review in conjunction with the SITC 27th Annual Meeting. There are no fees to submit abstracts.

Abstracts submitted by the July 11, 2012 deadline will be reviewed by a committee for selection of oral and poster presentations at the SITC 27th Annual Meeting. All accepted abstracts will be published in the *Journal of Immunotherapy*, an official journal of SITC. Abstract authors that denote themselves and qualify as “Young Investigators” are eligible for the SITC Presidential Award and SITC Travel Award consideration. See page 19 for more information on awards.

ABSTRACT CATEGORIES

- Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
- Combining Immunotherapy and Other Therapies
- DC Subsets/Cancer Vaccines
- Immunity of Oncolytic Viruses
- Immunotherapy Combinations*
- Innate Immunity in Cancer*
- Single Cell High Throughput Technologies Immune Monitoring
- T Cell Manufacture and Potency Testing
- T Cell Modulating Strategies
- Targeted Therapies and Anti-Tumor Immunity*
- Targeting Immune Suppression
- Therapeutic Monoclonal Antibodies in Cancer*
- Tumor Microenvironment*
- Tumor Vasculature, Chemokines and Lymphocyte Trafficking to the Tumor*

** Denotes poster only category. Abstracts submitted in these categories will be eligible for poster presentations only. However, abstracts submitted in these categories and noted as eligible for Young Investigator Awards will be considered for both poster and oral presentations.*

GUIDELINES FOR AUTHORS

Authors submitting abstracts to the SITC 27th Annual Meeting must agree to the following:

- Serve as the contact for all correspondence about the abstract and inform co-authors about its status.
- Confirm all authors are aware of and agree to the content and data presented in the abstract.
- Verify the abstract is accurate and that permission has been obtained from all relevant parties.
- Verify the data presented in the abstract has not been published prior to the SITC 27th Annual Meeting.
- Agree that abstracts submitted to SITC 27th Annual Meeting are embargoed until October 22, 2012.
- Agree that, if accepted, they or a co-author will present the abstract at the SITC 27th Annual Meeting.

Abstracts cannot be withdrawn after the abstract submission deadline.

Submitting an abstract for the SITC 27th Annual Meeting does not constitute registration for the conference. Abstract presenters must register to attend the meeting by completing the registration form on page 27 or by registering online at www.sitcancer.org.

ABSTRACT SUBMISSION INSTRUCTIONS

Abstract submission will be available on the SITC website from May 7 - July 11, 2012.

To submit an abstract for the SITC 27th Annual Meeting:

1. Select the “Submit an Abstract” link at <http://www.sitcancer.org/2012/abstracts>.
2. Review the abstract topics and guidelines for authors.
3. Follow the online instructions to create a login name and password.
Please remember this information as it is needed to access your abstract for editing.

4. Complete the following sections:

- | | |
|--------------------------------|-----------------------------|
| - Contact Author Information | - Author Affiliations |
| - Abstract Text | - Author Listing |
| - Funding Source | - Presenter Disclosure |
| - Category/Presentation Type | - Table Creation (optional) |
| - Keywords | - Image Upload (optional) |
| - Award Eligibility (optional) | - Copyright Waiver |

5. Submit your abstract or save it for future editing.

Abstracts can be revised as many times as desired prior to the deadline. However, all draft abstracts must be submitted by the July 11 deadline to be considered for presentation. Submissions still in draft form will not be reviewed. After July 11, no changes or submissions will be accepted.

QUESTIONS

For general questions regarding abstracts, please contact the SITC office at 414-271-2456 or education@sitcancer.org.

For questions regarding the abstract site and submission, please contact SITC’s abstract vendor, ScholarOne, by selecting the “Get Help Now” button on the abstract submission site and emailing them at ts.acsupport@thomsonreuters.com or calling 434-964-4100, weekdays from 12:00 am - 8:30 pm Eastern Time.

ABSTRACT NOTIFICATIONS

Abstract notifications will be sent to contact authors via email on August 13, 2012.

Abstract Submission Deadline
July 11, 2012 • 11:59 pm PST

SITC supports growth and achievement among young investigators in the field of cancer immunotherapy. To fulfill this goal, SITC will offer these special opportunities for young investigators and early career scientists at the SITC 27th Annual Meeting.

ABSTRACT AWARDS

In 2012, SITC will offer 10 Young Investigator Awards recognizing excellence in oral abstract and poster presentations at the SITC 27th Annual Meeting.

How to Apply

To be considered for an award, an abstract must be submitted online by the deadline of July 11, 2012. Guidelines and instructions for submitting abstracts can be found on page 18. During the online submission process, you must select the “Apply” button in the “Awards” section to be considered for an award.

Award Eligibility

To qualify for a Young Investigator Award, the primary/presenting author must meet the young investigator criteria:

- Primary/presenting author must be one of the following:
 - student
 - postdoctoral research fellow
 - clinical fellow or
 - junior faculty (instructor or assistant professor) with three or less years (total from all institutions) on staff.
- Qualified individual must be listed as both the primary author and the presenting author on the abstract.
- Authors selected for oral presentations must be capable and comfortable presenting the abstract to a large audience and answering audience questions.
- Individuals who have previously won the Presidential Award are ineligible for the same award.

PRESIDENTIAL AWARDS

Four qualified abstracts submitted in any category and authored by young investigators will be selected for a 20-minute oral presentations during the Presidential Session held on Saturday, October 27. Of those abstract presenters, one will be selected as the 2012 Presidential Award recipient by a committee of members from the SITC Board of Directors. The recipient will be announced during the Saturday Presidential Reception.

SITC Presidential Award recipient will receive:

- \$1,000 Honorarium
- Up to \$1,000 in Travel Reimbursement
- 1-Year Membership with SITC
- Commemorative Presidential Award Plaque
- Presidential Award Winner Poster Ribbon

SITC Presidential Travel Award recipients will receive:

- Up to \$750 in Travel Reimbursement
- 1-Year Membership with SITC
- Presidential Travel Award Certificate
- Presidential Travel Award Winner Poster Ribbon

SITC TRAVEL AWARDS

SITC will offer six travel awards to selected young investigators presenting a poster at the SITC 27th Annual Meeting. Selection of award recipients will be done by a committee of SITC leadership. Recipients will be notified prior to the meeting, but will be recognized during the Presidential Reception on Saturday evening.

SITC Travel Award recipients will receive:

- Up to \$750 in Travel Reimbursement
- SITC Travel Award Winner Certificate
- SITC Travel Award Winner Poster Ribbon

For questions regarding award eligibility, submission deadlines, or other related abstract questions, please contact the SITC office at 414-271-2456 or education@sitcancer.org.

For SITC 2012, the ECS Committee has organized several events to connect early career scientists with leaders in the field of cancer immunotherapy on a variety of career development topics. The events are intended for graduate, medical, and post baccalaureate students; clinical fellows; postdoctoral fellows; assistant professors; and other early career professionals. Space for these events is limited and priority will be given to early career scientists. Please register in advance.

EVENING NETWORKING EVENT

Friday, October 26, 2012

8:00 pm - 10:00 pm

All students and early career scientists are invited to attend this informal networking event. Located at the meeting venue, this event is a great way to meet with peers in the field. Pizza and salad will be provided and a cash bar will be available. Pre-registration is required for this event.

"MEET-THE-EXPERT" BREAKFAST

Saturday, October 27, 2012

7:00 am - 7:45 am

Program Purpose

The "Meet-the-Expert" Breakfast will focus on unique issues related to the career development of early career scientists. Key leaders in the field will facilitate roundtable discussions on particular areas of interest. Registered attendees of the "Meet-the-Expert" Breakfast may submit questions for discussion in advance or pose questions to the experts at the table. Experts will answer questions and lead informal dialogues to help provide guidance and direction. Space is limited; please register for your topic of choice on page 26. Continental Breakfast will be provided.

Organizers

Christian Capitini, MD - *University of Wisconsin*

William Redmond, PhD - *Earle A. Chiles Research Institute*

Intended Audience

The audience for this educational program includes graduate, medical, and post-baccalaureate students; clinical fellows; postdoctoral fellows; assistant professors; and other early career professionals.

Topics (ticketed event)

- **Developing Successful Collaborations**
Leader: Pamela S. Ohashi, PhD - *Ontario Cancer Institute*
- **Finding Your Niche**
Leader: Edward Nelson, MD - *University of California Irvine*
- **Grant Writing**
Leader: Paul Sondel, MD, PhD - *University of Wisconsin*
- **Publishing Papers**
Leader: Francesco Marincola, MD - *National Institutes of Health*
- **Translational Research**
Leader: Padmanee Sharma, MD, PhD - *MD Anderson Cancer Center*
- **Managing a Research Lab**
Leader: Nicholas Gascoigne, PhD - *The Scripps Research Institute*
- **Work-Life Balance**
Leader: Charles G. Drake, MD, PhD - *Johns Hopkins University*

Program Goals

- Produce scientifically significant discussions and provide guidance relevant to the career development of early career scientists.
- Provide early career scientists with an opportunity to meet key experts in the field and facilitate interactions in an informal small-group setting.
- Mentor early career scientists on the state of research in today's environment through expert guidance on timely and relevant topics in cancer immunotherapy.

Expected Learner Outcomes

Upon completion of this program, the participants will be able to:

- Locate resources available that will facilitate career development related to grant writing, finding one's niche, publishing papers, collaborations, translational research, and/or laboratory management.
- Develop a framework for action, with an understanding of the complexities and potential pitfalls related to the key issue under discussion.
- Summarize answers provided by experts in the field to specific questions related to the career development topic.
- Implement improved processes of communication between early career scientists and established researchers and experts.

T CELL MODULATING STRATEGIES

(Friday, October 26, 8:45 am - 11:30 am)

Multiple T cell subsets may be involved in responses to cancer. Pharmacological and genetic strategies allow specific selection or activation of certain subsets with higher potency to fight cancer. The functional activity of immune modulating agents and adoptive cell transfer therapy can vary depending on which lymphocyte subset is being activated. The phenotype and function of lymphocytes with greater ability to become memory cells, as well as progenitors to memory cells, are being defined; opening the door to their specific use in immunotherapy strategies.

DC SUBSETS/CANCER VACCINES

(Friday, October 26, 1:30 pm - 3:00 pm)

Dendritic cells (DC) continue to arouse interest because of their central role in initiation and regulation of cell-mediated immune responses. This year, the specialization in function of different subsets of human DC will be highlighted, particularly with respect to their use in immunotherapeutic strategies. Recent advances in the use of different DC subsets in clinical trials will be discussed as well as a comparison of immunotherapy with ex vivo prepared DC versus direct in vivo targeting of DC with cancer vaccines or other immuno-therapeutics.

Cancer vaccines come in different modalities. The specifications for cancer vaccines will be discussed as well as the immunomonitoring assays required to establish their mode of action and potency. In addition, the synergy of cancer vaccines with other cancer treatment modalities will be highlighted, including synergy with chemotherapy, irradiation, and checkpoint control monoclonal antibodies.

TARGETING IMMUNE SUPPRESSION

(Friday, October 26, 1:30 pm - 3:00 pm)

Regulatory mechanisms counteract effective eradication of cancers by immune effector cells. The identification of these pathways has allowed the identification of novel strategies to potentiate immunotherapy of cancers. In this session, the nature of the most frequent inhibitory pathways will be discussed; followed by their elimination in preclinical models and clinical trials. The session will address targeting of Tregs, MDSC, CTLA-4, PD-1, IDO, and NO in the tumor microenvironment and elsewhere.

IMMUNITY OF ONCOLYTIC VIRUSES

(Friday, October 26, 3:15 pm - 5:15 pm)

Oncolytic viruses selectively kill cancer cells while sparing normal cells. The mechanisms by which this has been achieved as well as further improvements in cancer cell selectivity will be discussed. Preclinical models and clinical trials with oncolytic viruses will be highlighted. Finally, oncolytic virus exploitation of immune mechanisms and the prospect of further enhancement of these by additional highly specific immunotherapy will be discussed.

COMBINING IMMUNOTHERAPY AND OTHER THERAPIES

(Saturday, October 27, 8:45 am - 11:30 am)

As new generations of highly targeted therapies are being developed for the treatment of cancer, it is important to understand how they impact the immune system and how to combine them with immunotherapies. Many of these targeted therapies have high initial antitumor activities but are limited by the development of acquired resistance. Their combination with immune modulating agents may allow inducing more durable tumor responses. Since the targeted therapies are usually systemic therapies then they may have additional effects on the immune system, which may potentiate or counteract the antitumor activity of immunotherapies. Therefore, it is of great importance to gain a detailed molecular understanding of how they differentially impact on lymphocytes and cancer cells.

T CELL MANUFACTURE AND POTENCY TESTING

(Saturday, October 27, 1:30 pm - 3:00 pm)

The clinical effectiveness of tumor infiltrating lymphocyte (TIL) therapy for the treatment of metastatic melanoma has improved as have the methods used to produce TIL. As a result, TIL treatment is becoming more widespread and multicenter clinical trials with centralized TIL processing are being considered. Progress in the development of centralized GMP methods for TIL production and the identification of possible TIL potency markers will be discussed.

SINGLE CELL HIGH THROUGHPUT TECHNOLOGIES IMMUNE MONITORING

(Saturday, October 27, 1:30 pm - 3:00 pm)

New technologies for immune monitoring are increasing our understanding of how the immune system can be turned on to fight cancer. Advances in immune monitoring allow multiparametric analyses in immune cells, which can more readily define the effects of immunotherapies compared to older platforms based on single readouts of effector functions or quantitation of lymphocytes with a particular tumor specificity. This includes the use of technologies that allow combined surface phenotype and intracellular signaling analyses of multiple proteins as well as multiplexed assays for time-course evaluation of immune responses.

ADOPTIVE T CELL TRANSFER AND CELL THERAPY AS CANCER IMMUNOTHERAPY (CARS)

(Sunday, October 28, 8:00 am - 10:15 am)

Adoptive T cell transfer and cell therapy are evolving cancer immunotherapy approaches with promising clinical activity. These therapies are being used for a greater number of cancer patients and their efficacy is being improved by using selected T cell populations, reprogramming T cells, and genetically engineering T cells. The most recent scientific approaches and clinical trials will be reviewed.

(Schedule subject to change)

FRIDAY, OCTOBER 26

7:00 am - 7:45 am	New Member Breakfast Gathering
7:00 am - 7:45 am	Continental Breakfast
7:50 am - 8:00 am	SITC 27th Annual Meeting Begins/President's Welcome
	Thomas F. Gajewski, MD, PhD - <i>University of Chicago</i>
8:00 am - 8:45 am	Richard V. Smalley, MD Memorial Lectureship
	Theresa L. Whiteside, PhD - <i>University of Pittsburgh Cancer Institute</i>
8:45 am - 11:30 am	Plenary Session 301: T Cell Modulating Strategies
	Co-chairs:
	Nicholas P. Restifo, MD - <i>National Cancer Institute</i>
	Cassian Yee, MD - <i>Fred Hutchinson Cancer Research Center</i>
	Invited Speakers:
	Pamela S. Ohashi, PhD - <i>Ontario Cancer Institute</i>
	Nicholas P. Restifo, MD - <i>National Cancer Institute</i>
	Cassian Yee, MD - <i>Fred Hutchinson Cancer Research Center</i>
11:30 am - 1:30 pm	<i>Lunch with Exhibits, Poster Viewing and Presentations</i>
1:30 pm - 3:00 pm	Concurrent Session 304: DC Subsets/Cancer Vaccines
	Co-chairs and Invited Speakers:
	Pawel Kalinski, MD, PhD - <i>University of Pittsburgh Cancer Institute</i>
	Cornelis J.M. Melief, MD, PhD - <i>Leiden University Medical Center</i>
1:30 pm - 3:00 pm	Concurrent Session 305: Targeting Immune Suppression
	Co-chairs and Invited Speakers:
	David H. Munn, PhD - <i>Georgia Health Sciences University</i>
	Michael H. Kershaw, PhD - <i>Peter MacCallum Cancer Center</i>
3:00 pm - 3:15 pm	<i>Refreshments and Networking</i>
3:15 pm - 5:15 pm	Plenary Session 306: Immunity of Oncolytic Viruses
	Co-chairs:
	Howard L. Kaufman, MD, FACS - <i>Rush University Medical Center</i>
	Aladar A. Szalay, PhD - <i>Genelux Corporation</i>
	Invited Speakers:
	Edmund C. Lattime, PhD - <i>The Cancer Institute of New Jersey</i>
	Richard Vile, PhD - <i>Mayo Clinic</i>
5:15 pm - 5:30 pm	Plenary Session 307: World Immunotherapy Council (WIC) Update
	Bernard A. Fox, PhD - <i>Earle A. Chiles Research Institute</i>
5:30 pm - 5:45 pm	Plenary Session 308: US Food and Drug Administration (FDA) Update
	Raj K. Puri, MD, PhD - <i>US Food and Drug Administration, CBER</i>
5:45 pm - 6:15 pm	SITC Membership Business Meeting
	<i>SITC members and potential members are invited to attend</i>
Immediately following the Business Meeting - 8:00 pm	Poster and Networking Reception
8:00 pm - 10:00 pm	Early Career Scientists Evening Networking Event

(Schedule subject to change)

SATURDAY, OCTOBER 27

7:00 am - 7:45 am	Early Career Scientists “Meet-the-Expert” Breakfast
7:00 am - 8:00 am	Continental Breakfast
8:00 am - 8:45 am	Keynote Address
	Robert D. Schreiber, PhD - <i>Washington University St. Louis</i>
8:45 am - 11:30 am	Plenary Session 401: Combining Immunotherapy and Other Therapies
	Co-chairs:
	Antoni Ribas, MD - <i>UCLA Medical Center</i>
	Laurence Zitvogel, MD, PhD - <i>Institute Gustave Roussy</i>
	Invited Speakers:
	Ronald DeMatteo, MD, FACS - <i>Memorial Sloan-Kettering Cancer Center</i>
	Antoni Ribas, MD - <i>UCLA Medical Center</i>
	Laurence Zitvogel, MD, PhD - <i>Institute Gustave Roussy</i>
11:30 am - 1:30 pm	<i>Lunch with Exhibits, Poster Viewing and Presentations</i>
1:30 pm - 3:00 pm	Concurrent Session 404: T Cell Manufacture and Potency Testing
	Co-chairs:
	Daniel J. Powell, Jr., PhD - <i>University of Pennsylvania</i>
	David F. Stroncek, MD - <i>National Institutes of Health</i>
	Invited Speakers:
	Laszlo G. Radvanyi, PhD - <i>MD Anderson Cancer Center</i>
	Jon Rowley, MS, PhD - <i>Lonza Walkersville, Inc.</i>
1:30 pm - 3:00 pm	Concurrent Session 405: Single Cell High Throughput Technologies Immune Monitoring
	Co-chairs:
	Alessandra Cesano, MD, PhD - <i>Nodality</i>
	Begonya Comin-Anduix, PhD - <i>UCLA School of Medicine</i>
	Invited Speakers:
	Alessandra Cesano, MD, PhD - <i>Nodality</i>
	Garry P. Nolan, PhD - <i>Stanford School of Medicine</i>
3:00 pm - 3:30 pm	<i>Refreshments and Networking</i>
3:30 pm - 4:50 pm	Plenary Session 406: Presidential Abstract Session
	Chair:
	Thomas F. Gajewski, MD, PhD - <i>University of Chicago</i>
4:50 pm - 5:20 pm	Plenary Session 407: National Cancer Institute (NCI) Update
	William Merriitt, PhD - <i>National Cancer Institute</i>
5:20 pm - 5:50 pm	Plenary Session 408: Cancer Immunotherapy Trials Network (CITN) Update
5:50 pm - 6:15 pm	Awards Ceremony
Immediately following the Awards Ceremony - 8:00 pm	Presidential Reception with Poster Viewing
8:00 pm	<i>The Checkpoints Performance</i>

(Schedule subject to change)

SUNDAY, OCTOBER 28

7:00 am - 8:00 am	Continental Breakfast
8:00 am - 10:15 am	Plenary Session 500: Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
	Co-chairs:
	Philip D. Greenberg, MD - <i>University of Washington</i>
	Steven A. Rosenberg, MD, PhD - <i>National Cancer Institute</i>
	Invited Speakers:
	Philip D. Greenberg, MD - <i>University of Washington</i>
	Steven A. Rosenberg, MD, PhD - <i>National Cancer Institute</i>
	Michel Sadelain, MD, PhD - <i>Memorial Sloan-Kettering Cancer Center</i>
10:15 am	Annual Meeting Adjourns
10:15 am - 10:30 am	<i>Refreshments and Networking</i>
10:30 am - 12:00 pm	Hot Topic Symposium

HOT TOPIC SYMPOSIUM

Each year immediately following the conclusion of the Annual Meeting, the Society hosts a 1½ hour Hot Topic Symposium to address a rapidly developing key issue in the field of cancer immunotherapy. In this final program, leaders in the field deliver dynamic presentations on cutting-edge research and participate in interactive question and answer sessions with the audience.

This list includes confirmed Faculty for SITC 2012 as of 05/25/2012.

PROFESSIONAL DEVELOPMENT SESSION FACULTY

Organizers

Christian Capitini, MD
University of Wisconsin

William Redmond, PhD
Earle A. Chiles Research Institute

Invited Speakers

Ana Anderson, PhD
Harvard Medical School

Lisa H. Butterfield, PhD
University of Pittsburgh

Shari Pilon-Thomas, PhD
H. Lee Moffitt Cancer Center & Research Institute

Raj K. Puri, MD, PhD
US Food and Drug Administration, CBER

Amy Wesa, PhD
Celsense, Inc.

WORKSHOP FACULTY

Organizers

Leisha Emens, MD, PhD
Johns Hopkins University

Jerome Galon, PhD
INSERM-Cordeliers Research Center

Samuel C. Silverstein, MD
Columbia University

Keynote Speakers

Glenn Dranoff, MD
Dana-Farber Cancer Institute

Nicholas P. Restifo, MD
National Cancer Institute

Invited Speakers

Ivan Borrello, MD
Johns Hopkins University School of Medicine

Philippe Bousso
INSERM U668

Vincenzo Bronte, MD
University of Verona

Laurence J.N. Cooper, MD, PhD
MD Anderson Cancer Center

George Coukos, MD, PhD
University of Pennsylvania Medical Center

Pierre G. Coulie, MD, PhD
De Duve Institute and University of Louvain

Mary Disis, MD
University of Washington

Leisha Emens, MD, PhD
Johns Hopkins University

Dean W. Flesher, MD, PhD
Stanford University School of Medicine

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Dmitry I. Gabrilovich, MD, PhD
H. Lee Moffitt Cancer Center and Research Institute

Thomas F. Gajewski, MD, PhD
University of Chicago

Jerome Galon, PhD
INSERM-Cordeliers Research Center

Nicholas Gascoigne, PhD
The Scripps Research Institute

Ulrich Hoffmueller, MBA, PhD
Epiontis GmbH

Alessandro Lugli, MD
Institut of Pathology University of Bern

Francesco Marincola, MD
National Institutes of Health

David Munn, MD
Georgia Health Sciences University

Drew Pardoll, MD, PhD
Johns Hopkins University School of Medicine

Antoni Ribas, MD
UCLA Medical Center

Brian Rini, PhD
Cleveland Clinic Taussig Center

Hans Schreiber, MD
University of Chicago

Samuel C. Silverstein, MD
Columbia University

Weiping Zou, MD, PhD
University of Michigan

PRIMER FACULTY

Organizers

Charles G. Drake, MD, PhD
Johns Hopkins University

Mario Sznol, MD
Yale University School of Medicine

Invited Speakers

Madhav Dhodapkar, MD
Yale University

Charles G. Drake, MD, PhD
Johns Hopkins University

Susan Kaech, PhD
Yale University

Willem Overwijk, MD
MD Anderson Cancer Center

Jonathan Powell, MD
Johns Hopkins Hospital

Pedro Romero, MD
University of Lausanne

Louis Weiner, MD
Georgetown University Medical Center

Cassian Yee, MD
Fred Hutchinson Cancer Research Center

ANNUAL MEETING FACULTY

Organizers

Cornelis Melief, MD, PhD
Leiden University Medical Center

Antoni Ribas, MD
UCLA Medical Center

David Stroncek, MD
National Institutes of Health

Session Chairs:

Alessandra Cesano, MD, PhD
Nodality

Begonya Comin-Anduix, PhD
UCLA School of Medicine

Thomas F. Gajewski, MD, PhD
University of Chicago

Phillip Greenberg, MD
University of Washington

Pawel Kalinski, MD, PhD
University of Pittsburgh Cancer Institute

Howard Kaufman, MD, FACS
Rush University Medical Center

Michael H. Kershaw, PhD
Peter MacCallum Cancer Centre

Cornelis Melief, MD, PhD
Leiden University Medical Center

David Munn, MD
Georgia Health Sciences University

Daniel J. Powell
University of Pennsylvania

Nicholas P. Restifo, MD
National Cancer Institute

Antoni Ribas, MD
UCLA Medical Center

Steven Rosenberg, MD, PhD
National Cancer Institute

Aladar A. Szalay, PhD
Genelux Corporation

David Stroncek, MD
National Institutes of Health

Cassian Yee, MD
Fred Hutchinson Cancer Research Center

Laurence Zitvogel, MD, PhD
Institute Gustave Roussy

Invited Speakers

Alessanda Cesano, MD, PhD
Nodality

Ronald DeMatteo, MD, FACS
Memorial Sloan-Kettering Cancer Center

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Thomas F. Gajewski, MD, PhD
University of Chicago

Phillip Greenberg, MD
University of Washington

Pawel Kalinski, MD, PhD
University of Pittsburgh Cancer Institute

Michael H. Kershaw, PhD
Peter MacCallum Cancer Centre

Edmund C. Lattime, PhD
The Cancer Institute of New Jersey

Cornelis Melief, MD, PhD
Leiden University Medical Center

William Merritt, PhD
National Cancer Institute

David Munn, MD
Georgia Health Sciences University

Gary Nolan, PhD
Stanford School of Medicine

Pamela S. Ohashi, PhD
Ontario Cancer Institute

Raj K. Puri, MD, PhD
US Food and Drug Administration, CBER

Laszlo G. Radvanyi, PhD
MD Anderson Cancer Center

Nicholas P. Restifo, MD
National Cancer Institute

Antoni Ribas, MD
UCLA Medical Center

Steven Rosenberg, MD, PhD
National Cancer Institute

Jon Rowley, MS, PhD
Lonza Walkersville, Inc.

Michel Sadelain, MD, PhD
Memorial Sloan-Kettering Cancer Center

Richard Vile, PhD
Mayo Clinic

Cassian Yee, MD
Fred Hutchinson Cancer Research Center

Laurence Zitvogel, MD, PhD
Institute Gustave Roussy

Keynote Speaker

Robert D. Schreiber, PhD
Washington University St. Louis

**Richard V. Smalley, MD Memorial
Lectureship Award Recipient/Keynote
Speaker**

Theresa L. Whiteside, PhD
University of Pittsburgh Cancer Institute

ECS BREAKFAST FACULTY

Organizers

Christian Capitini, MD
University of Wisconsin

William Redmond, PhD
Earle A. Chiles Research Institute

Table Leaders

Charles G. Drake, MD, PhD
Johns Hopkins University

Nicholas Gascoigne, PhD
The Scripps Research Institute

Francesco Marincola, MD
National Institutes of Health

Edward Nelson, MD
University of California-Irvine

Pamela S. Ohashi, PhD
Ontario Cancer Institute

Padmanee Sharma, MD, PhD
MD Anderson Cancer Center

Paul Sondel, MD, PhD
University of Wisconsin

HOT TOPIC SYMPOSIUM FACULTY

Organizers

Cornelis Melief, MD, PhD
Leiden University Medical Center

Antoni Ribas, MD
UCLA Medical Center

David Stroncek, MD
National Institutes of Health

October 24-28, 2012

Bethesda North Marriott Hotel & Conference Center, Bethesda, MD, USA

Name: _____

Academic Degree: (please circle) MD PhD RN MS NP PharmD Other: _____

Institution/Company: _____

Title: _____ Dept: _____

Mailing Address: _____

City: _____ State: _____ Postal Code: _____

Country: _____ Email: _____

Phone: _____ Fax: _____

Work Sector (check one):

☐ Academia ☐ Government ☐ Industry/Corporate ☐ Not-for-Profit Organization

Practice or Work Setting (check one):

☐ Clinic ☐ Government ☐ Hospital ☐ Lab ☐ Lab & Clinic (translational) ☐ Medical School/University
☐ Pharmaceutical/Biotech ☐ None

Field(s) of specialty (check all that apply):

<input type="checkbox"/> Cell Biology	<input type="checkbox"/> Immunotherapy	<input type="checkbox"/> Pediatric Oncology	<input type="checkbox"/> Stem Cell Biology
<input type="checkbox"/> Dermatology	<input type="checkbox"/> Internal Medicine	<input type="checkbox"/> Pharmacology/ Toxicology	<input type="checkbox"/> Surgical Oncology
<input type="checkbox"/> Genetics	<input type="checkbox"/> Medical Oncology	<input type="checkbox"/> Radiation Oncology	<input type="checkbox"/> Transplantation
<input type="checkbox"/> Gynecologic Oncology	<input type="checkbox"/> Microbiology	<input type="checkbox"/> Radiology	<input type="checkbox"/> Others _____
<input type="checkbox"/> Hematology	<input type="checkbox"/> Molecular Biology		

Disease state(s) (check those most affiliated with your research or practice):

<input type="checkbox"/> Breast	<input type="checkbox"/> Hepatocellular	<input type="checkbox"/> Lung	<input type="checkbox"/> Neuroblastoma	<input type="checkbox"/> Renal Cell
<input type="checkbox"/> Colorectal	<input type="checkbox"/> Kidney	<input type="checkbox"/> Lymphoma	<input type="checkbox"/> Ovarian	<input type="checkbox"/> Others _____
<input type="checkbox"/> Head & Neck	<input type="checkbox"/> Leukemia	<input type="checkbox"/> Melanoma	<input type="checkbox"/> Prostate	

☐ I do not wish to be included in the registration listings that are part of the registration materials.

Special needs (physical, dietary, religious). Please list: _____

Registration Instructions:

Please note your registration classification to determine the correct program fees. For non-members, your classification is determined by your primary institution. Non-Member Students and Fellows-in-Training are required to provide proof of enrollment or a letter from a lab supervisor with this form. Allied Health Professionals are non- MD, PhD or PharmD individuals such as nurses, physician assistants, or lab technicians. Registration is limited for all SITC events. *You will be notified in advance if your preferences cannot be accommodated.*

PROFESSIONAL DEVELOPMENT SESSION **NEW!**

The following activity is for individuals who are early in their career. Priority will be given to Early Career Scientists. For more information see page 5.

☐ I understand that the intended audience is early career scientists.

Professional Development Session

☐ Wednesday, October 24, 2012 (1:30 pm - 5:30 pm)

Early
Registration Fee
(by Sept. 9)

\$35

Regular
Registration Fee
(Sept. 10-24)

\$40

Fill in the
appropriate fee:

\$ _____

SITC WORKSHOP REGISTRATION

	Early Registration Fee (by Sept. 9)	Regular Registration Fee (Sept. 10-24)	Fill in the appropriate fee:
Wednesday, October 24 - Thursday, October 25, 2012			
Members:	\$270	\$320	
One Day Only - Please indicate day: <input type="checkbox"/> Wednesday <input type="checkbox"/> Thursday	\$140	\$170	
Members (Scientist-in-Training/Student):	\$120	\$180	
One Day Only - Please indicate day: <input type="checkbox"/> Wednesday <input type="checkbox"/> Thursday	\$70	\$95	
Non-Members (Academic/Government):	\$300	\$350	
One Day Only - Please indicate day: <input type="checkbox"/> Wednesday <input type="checkbox"/> Thursday	\$160	\$180	
Non-Members (Industry):	\$500	\$550	
One Day Only - Please indicate day: <input type="checkbox"/> Wednesday <input type="checkbox"/> Thursday	\$260	\$280	
Non-Members (Students*/Allied Health):	\$150	\$200	
One Day Only - Please indicate day: <input type="checkbox"/> Wednesday <input type="checkbox"/> Thursday	\$80	\$110	\$ _____

SITC PRIMER REGISTRATION

	Early Registration Fee (by Sept. 9)	Regular Registration Fee (Sept. 10-24)	Fill in the appropriate fee:
Thursday, October 25, 2012 (8:00 am - 5:00 pm)			
Members:	\$150	\$200	
Members (Scientist-in-Training/Student):	\$75	\$100	
Non-Members (Academic/Government):	\$200	\$250	
Non-Members (Industry):	\$400	\$450	
Non-Members (Students*/Allied Health):	\$100	\$125	\$ _____

SITC 27TH ANNUAL MEETING REGISTRATION

	Early Registration Fee (by Sept. 9)	Regular Registration Fee (Sept. 10-24)	Fill in the appropriate fee(s):
Friday, October 25 - Sunday, October 28, 2012			
Members:	\$595	\$650	
One Day Only - Please indicate day: <input type="checkbox"/> Friday <input type="checkbox"/> Saturday <input type="checkbox"/> Sunday	\$275	\$300	
Members (Scientist-in-Training/Student):	\$275	\$310	
One Day Only - Please indicate day: <input type="checkbox"/> Friday <input type="checkbox"/> Saturday <input type="checkbox"/> Sunday	\$165	\$175	
Non-Members (Academic/Government):	\$650	\$725	
One Day Only - Please indicate day: <input type="checkbox"/> Friday <input type="checkbox"/> Saturday <input type="checkbox"/> Sunday	\$300	\$325	
Non-Members (Industry):	\$1,125	\$1,200	
One Day Only - Please indicate day: <input type="checkbox"/> Friday <input type="checkbox"/> Saturday <input type="checkbox"/> Sunday	\$475	\$525	
Non-Members (Students*/Allied Health):	\$310	\$345	
One Day Only - Please indicate day: <input type="checkbox"/> Friday <input type="checkbox"/> Saturday <input type="checkbox"/> Sunday	\$175	\$185	
Spouse/Guest Registration			
Registered spouses/guests will ONLY be admitted to the SITC 27 th Annual Meeting social activities. Society members or authors/co-authors of abstracts may not use the guest registration.		Guest Fee \$125	
Name of Spouse/Guest: _____			\$ _____

*Proof of enrollment required

SITC 27TH ANNUAL MEETING ACTIVITIES

Early Career Scientists Activities

These activities are offered for individuals who are early in their career; priority will be given to Early Career Scientists. For more information see page 5. ☐ Yes, I qualify as an Early Career Scientist.

Please indicate if you will be attending these activities:

Evening Networking Event (Complimentary with Annual Meeting Registration)

☐ Friday, October 26, 2012 (8:00 pm - 10:00 pm)

"Meet-the-Expert" Breakfast (Complimentary with Annual Meeting Registration)

Saturday, October 27, 2012 (7:00 am - 7:45 am)

The following sessions run concurrently and space is limited, pre-registration is required. Please mark your preference below.

- ☐ Session 450 - Developing Successful Collaborations - Pamela S. Ohashi, PhD
☐ Session 451 - Finding Your Niche - Edward Nelson, MD
☐ Session 452 - Grant Writing - Paul Sondel, MD, PhD
☐ Session 453 - Publishing Papers - Francesco Marincola, MD
☐ Session 454 - Translational Research - Padmanee Sharma, MD, PhD
☐ Session 455 - Managing a Research Lab - Nicholas Gascoigne, PhD
☐ Session 456 - Work-Life Balance - Charles G. Drake, PhD

SITC 27th Annual Meeting Concurrent Sessions

Please indicate your session choice:

- Friday: ☐ Session 304 - DC Subsets/Cancer Vaccines ☐ Session 305 - Targeting Immune Suppression
 Saturday: ☐ Session 404 - T Cell Manufacture and Potency Testing ☐ Session 405 - Single Cell High Throughput Technologies Immune Monitoring

SITC 27th Annual Meeting Social Activities

- ☐ Poster Reception - Friday, October 26, 2012
☐ Presidential Reception - Saturday, October 27, 2012
☐ The Checkpoints Performance - Saturday, October 27, 2012

HOT TOPIC SYMPOSIUM REGISTRATION

	Early Registration Fee (by Sept. 9)	Regular Registration Fee (Sept. 10-24)	Fill in the appropriate fee:
Sunday, October 28, 2012 (10:30 am - 12:00 pm)			
Delegates registered for SITC 2012 Annual Meeting:	Complimentary		
Other Attendees:	\$125	\$150	\$ _____

SITC "FRIEND OF THE SOCIETY" RIBBON/TRUST DONATIONS

SITC "Friend of the Society" Ribbon†	\$50 each	\$ _____	Fill in the appropriate contribution:
SITC Trust Donation†	Any amount	\$ _____	
†As a 501(c)(3) organization, donations made to SITC are tax-deductible as charitable contributions to the extent allowed by law.			\$ _____

PAYMENT INFORMATION:	
<i>Insert fees from the following sections to determine total registration fee.</i>	
Professional Development Session	\$
SITC Workshop	\$
SITC Primer	\$
SITC 27 th Annual Meeting	\$
Guest Registration	\$
Hot Topic Symposium	\$
SITC "Friend of the Society" Ribbon	\$
SITC Trust Donation	\$
Total Payment Due:	\$

Full payment must accompany this form.

Method of Payment:

☐ Check (enclosed) Make checks payable to SITC in U.S. dollars drawn from a U.S. bank.

☐ VISA ☐ MasterCard ☐ American Express ☐ Discover

Credit Card Number: _____

Expiration Date: _____

Cardholder's Name: _____

Cardholder's Signature: _____

CANCELLATION/REFUND POLICY

Refund requests should be submitted to the SITC office by September 24, 2012. A \$50 processing fee will be charged for all cancellations. All refunds will be processed after the programs. No refunds will be granted if cancellation is received after September 24, 2012. Special considerations will be given for health or family emergencies if requested in writing no later than 15 business days after the last day of the programs.

Mail completed form and full payment to:

SITC
555 E. Wells St., Suite 1100
Milwaukee, WI 53202 USA

Fax completed form to: 414-276-3349

Register online: www.sitcancer.org/2012/registration

Please contact the SITC office at 414-271-2456 or education@sitcancer.org with any questions.

SITC Profile

The Society for Immunotherapy of Cancer (SITC) was established in 1984 to facilitate the exchange and promotion of scientific information about the use of biological cancer therapies. SITC is a 501(c)(3) not for profit organization of medical professionals with a constituency of academic, government, industry, clinical, and basic scientists from around the world. The Society was founded on the belief that new systemic therapeutic treatments would continue to complement chemotherapies and move into the mainstream in the fight against cancer. To aid in this effort, SITC provides intimate channels for the discussion of current clinical trial results and methodologies, as well as means to collaborate on new initiatives in tumor immunology and biological therapy. It is these key interactions and innovations that help advance the progress of cancer research and therapies and lead to better patient outcomes.

Mission Statement

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

Core Values

- **Interaction/Integration:** Facilitate the exchange of information and education among basic and translational researchers, clinicians, young investigators, societies and groups sharing the mission of SITC
- **Innovation:** Challenge the thinking and seek the best research in the development of cancer immunotherapy
- **Translation:** Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
- **Leadership:** Define what is new and important and effectively communicate it to all relevant stakeholders

Membership

The Society for Immunotherapy of Cancer invites your support for our organization, its activities, and events by becoming a member. SITC fills its membership with those from industry, academia, and government, serving as clinical and basic scientists and industry representatives. Your contributions as a member can help shape SITC policy as we continue in our efforts to advance the development and application of cancer immunotherapy.

Through membership in SITC, you will be a member of an organization that is actively engaged in facilitating the implementation of timely, cutting-edge translational clinical research in cancer biotherapy.

Application Requirements

Regular applicants:

- Curriculum Vitae or educational resumé

Affiliate applicants:

- Business or educational resumé or Curriculum Vitae

Scientist-in-Training (Student) applicants:

- Proof of enrollment
- Letter of recommendation or Curriculum Vitae

SITC Membership Benefits:

- One year subscription to *Journal of Immunotherapy*, an official journal of SITC
- One year, online full-text access to *Journal of Immunotherapy*
- Reduction in submission fees and opportunity for rapid publication in SITC's subsection of the open-access *Journal of Translational Medicine*
- Reduction in registration fees for SITC Annual Meeting and Associated Programs
- Free access to speaker presentations and slide sets from past SITC live events
- Online directory of SITC members
- Access to "Members Only" section of SITC website: www.sitcancer.org
- Eligibility to serve on SITC committees
- Eligibility to serve on SITC Board of Directors (Regular members)
- Discount on SITC enduring materials

Additional Benefits:

- Access to the best science in the field
- Early access to timely information on what is new and relevant to biological approaches for the treatment of cancer
- Opportunities to participate in and shape discussions that guide progress in the field
- Opportunities to network with colleagues to develop new ideas, establish new collaborations to advance your work, and participate in active scientific exchange
- Access to luminaries in the field, including leading scientists and clinical researchers
- Guidance on relevant and timely issues
- The opportunity to advance your career

Membership Types

Regular Membership (\$220 annual dues) Available to individuals with an MD or PhD in a biological science or the equivalent who are active, bona fide representatives of the international scientific community with a specialty or interest in a field related to the biological therapy of cancer. Regular membership includes the right to vote.

Affiliate Membership (\$220 annual dues) Available to individuals active or otherwise interested in the biological therapy of cancer. Affiliate membership does not include the right to vote.

Scientist-in-Training (Student) Membership (\$50 annual dues) Available to individuals enrolled in MD or PhD academic programs or those participating in postdoctoral fellowships and residency programs who show a demonstrated interest in biological therapy of cancer. Student membership includes an online only subscription to the *Journal of Immunotherapy*, but does not include the right to vote.

Please check the membership category you are applying for:

☐ Regular ☐ Affiliate ☐ Scientist-in-Training (Student)

Name: _____

Academic Degree: (please circle) MD PhD RN MS NP PharmD Other: _____

Institution/Company: _____

Title: _____ Dept: _____

Mailing Address: _____

City: _____ State: _____ Postal Code: _____

Country: _____ Email: _____

Phone: _____ Fax: _____

Work Sector (check one):

☐ Academia ☐ Government ☐ Industry/Corporate ☐ Not-for-Profit Organization

Practice or Work Setting (check one):

☐ Clinic ☐ Government ☐ Hospital ☐ Lab ☐ Lab & Clinic (translational) ☐ Medical School/University
☐ Pharmaceutical/Biotech ☐ None

Field(s) of specialty (check all that apply):

<input type="checkbox"/> Cell Biology	<input type="checkbox"/> Immunotherapy	<input type="checkbox"/> Pediatric Oncology	<input type="checkbox"/> Stem Cell Biology
<input type="checkbox"/> Dermatology	<input type="checkbox"/> Internal Medicine	<input type="checkbox"/> Pharmacology/ Toxicology	<input type="checkbox"/> Surgical Oncology
<input type="checkbox"/> Genetics	<input type="checkbox"/> Medical Oncology	<input type="checkbox"/> Radiation Oncology	<input type="checkbox"/> Transplantation
<input type="checkbox"/> Gynecologic Oncology	<input type="checkbox"/> Microbiology	<input type="checkbox"/> Radiology	<input type="checkbox"/> Others _____
<input type="checkbox"/> Hematology	<input type="checkbox"/> Molecular Biology		

Disease state(s) (check those most affiliated with your research or practice):

<input type="checkbox"/> Breast	<input type="checkbox"/> Hepatocellular	<input type="checkbox"/> Lung	<input type="checkbox"/> Neuroblastoma	<input type="checkbox"/> Renal Cell
<input type="checkbox"/> Colorectal	<input type="checkbox"/> Kidney	<input type="checkbox"/> Lymphoma	<input type="checkbox"/> Ovarian	<input type="checkbox"/> Others _____
<input type="checkbox"/> Head & Neck	<input type="checkbox"/> Leukemia	<input type="checkbox"/> Melanoma	<input type="checkbox"/> Prostate	

Application Requirements

Regular applicants:

☐ I will email my CV or educational resumé to info@sitcancer.org.
☐ My CV or educational resumé is enclosed.

Affiliate applicants:

☐ I will email my business or educational resumé to info@sitcancer.org.
☐ My business or educational resumé is enclosed.

Scientist-in-Training (Student) applicants:

☐ I will email my letter of recommendation or CV and proof of enrollment to info@sitcancer.org.
☐ My letter of recommendation or CV and proof of enrollment are enclosed.

Membership applications are reviewed throughout the year. Applicants will be contacted upon acceptance. Membership is valid from the date dues are paid in full until the end of that calendar year.

Membership Fee:

☐ Regular/Affiliate (\$220) ☐ Scientist-in-Training (Student) (\$50)
☐ Check (enclosed) Make checks payable to SITC in U.S. dollars drawn from a U.S. bank.
☐ VISA ☐ MasterCard ☐ American Express ☐ Discover

Card Holder: _____

Card Number: _____ Exp.: _____

Signature: _____ Date: _____

Return this form to: SITC • 555 E. Wells St., Suite 1100 • Milwaukee, WI 53202-3823
 Tel: 414-271-2456 • Fax: 414-276-3349 • Email: info@sitcancer.org • Web: www.sitcancer.org

Tara Withington, CAE
Executive Director

Angela Kilbert
Associate Executive Director

Sharon Kayne Chaplock, PhD
Director of Education, Meetings, & Publications

Jennifer Warren
Assistant Director of Communications

Margaret Lecey
Membership and Development Manager

Nadine Couto, CMP
Senior Meetings Manager

Amanda Knack
Education Manager

Celeste Stroh
Education and Meetings Coordinator

Haley Haas
Administrative Coordinator

Save the Date! SITC 2013
NOVEMBER 6-10, 2013 • NATIONAL HARBOR, MD

Share
SITC 2012
with your
colleagues!



Available faculty presentations from SITC 2012
will be posted online after the meeting.
Visit the SITC website at www.sitcancer.org
in November for more details.

